The use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis.
Liposomes loaded with rifampicin and isoniazid were used experimentally to treat mice with severe tuberculosis. The animals were distributed in four groups. The control group and the group treated with unloaded liposomes showed the severest disease. Both groups showed the lowest accumulated survival, about 50% after 30 days. The numbers of colony-forming-units (CFU) and root specific lung weight (RSLW) were the highest and the histopathology of the lung showed marked diffuse lesions. However, the group treated with unloaded liposomes showed significantly higher growth of M. tuberculosis compared with the control. The group treated with drug and drug loaded liposomes showed a higher survival, about 85% after 30 days, and the lowest values of CFU and RSLW. The lung histology revealed considerably less inflammation which was focal. The parameters evaluated indicated a significantly better response in the group of animals treated with rifampicin and isoniazid entrapped in liposomes.
D000818:Animals; D004359:Drug Therapy, Combination; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D008081:Liposomes / Q000008:administration & dosage*; D008168:Lung / Q000473:pathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D014677:Pharmaceutical Vehicles; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013234:Stem Cells / Q000473:pathology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000473:pathology
D008081:Liposomes; D014677:Pharmaceutical Vehicles; D007538:Isoniazid; D012293:Rifampin